PTGX
Protagonist Therapeutics (PTGX) Stock Valuation
Review Protagonist Therapeutics (PTGX) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 150.43
- Price to book
- 8.88
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $2.81B
- Premium or discount
- 253.88%
- Market cap
- $9.93B
Protagonist Therapeutics (PTGX) Stock Valuation research
The Protagonist Therapeutics valuation page presents the available multiples, profitability measures and BTI fair-value context for PTGX. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.